NRIX (Nurix Therapeutics Inc) Earnings per share for the last four quarters

Nurix Therapeutics (NRIX) is establishing a cutting-edge targeted protein degradation environment to combat oncology. The annual EPS (TTM) change reflects the dynamics of this process, while the 184.90 value indicates the yield status. Development relies on extensive outsourcing of late-stage testing, with the overall system's stability directly dependent on strict FDA safety regulations.
Nurix Therapeutics Inc - analytical breakdowns and key metrics (NRIX)

This indicator measures the rate of change in earnings per share over a rolling twelve-month period, allowing for an assessment of value generation efficiency relative to the market price. For Nurix Therapeutics (NRIX), the EPS YoY TTM percentage trend reflects the business's resilience to geopolitical risks within component supply chains and patent disputes, revealing the company's actual strength relative to the sector.